Kayle Leogrande, the former Rock Racing rider, has been banned for eight years by the United States Anti-Doping Agency. The 40-year-old rider tested positive for seven different banned substances in a doping control taken at the Dana Point Grand Prix this year.
Leogrande tested positive four Selective Androgen Receptor Modulators (Ostarine, RAD-140, LGD-4033 and Andarine), Ibutamoren (a growth hormone-like factor), GW1516 Sulfone (the 'exercise in a pill' drug), and the anti-estrogen drug Raloxifene. Leogrande did not request a hearing to contest the charges against him. He accepted a provisional suspension on May 25, 2017 and he has been disqualified for all results on or after April 30, 2017. The eight-year period of ineligibility of Leogrande began on May 25, 2017, the date he accepted a provisional suspension. The cyclist in addition has been disqualified from all competitive results obtained on and subsequent to April 30, 2017, including forfeiture of any medals, points, and prizes.
In a statement, USADA said Raloxifene and GW1516 Sulfone, a metabolite of GW1516, are prohibited substances in the class of Hormone and Metabolic Modulators; Ostarine, RAD140, LGD4033 and Andarine, are prohibited substances in the class of Anabolic Agents; and Ibutamoren is a prohibited substance in the class of Peptide Hormones, Growth Factors, Related Substances and Mimetics. These substances are prohibited at all times under the USADA Protocol for Olympic and Paralympic Movement Testing, the United States Olympic Committee National Anti-Doping Policies, and the International Cycling Union Anti-Doping Rules, all of which have adopted the World Anti-Doping Code and the World Anti-Doping Agency Prohibited List.
This was the second doping positive test for the cyclist. Leogrande had earlier served a doping ban of two years for using EPO, the banned blood booster, during the Superweek series in 2007 to his then-Rock Racing soigneur Suzanne Sonye. The cyclist had attempted to sue both former team soigneur Suzanne Sonye and former professional cyclist Matt Decanio - who posted a phone conversation in which Sonye described the confession of Leogrande to his website - for slander, but his lawsuit was struck down by the courts. The cyclist was later found guilty of an anti-doping rule violation by USADA because of his admission to Sonye and admitted to having used EPO.
The three-person, independent panel of arbitrators from the American Arbitration Association (AAA)/North American Court of Arbitration for Sport (CAS) ruled against the cyclist. The USADA arbitration was over an anti-doping control taken from Leogrande during the 2007 Superweek series in which it was alleged by the United States Anti-Doping Agency that Leogrande intentionally contaminated it with soap while giving the sample. In November 2007, Sonye signed the USADA affidavit in which it was said that she had first-hand knowledge of the contaminated sample in question as well as the doping practices of Leogrande, including use of testosterone and Erythropoietin (EPO).
The three-member arbitration panel then heard that Leogrande admitted to using Vicadin, Ventalin, and EPO to Rock Racing soigneur Suzanne Sonye following an in-competition test by the United States Anti-Doping Agency.
Get more information about News, Doping, SARMS, Steroids, HGH and PDS...
Subscribe to our Underground Evo mailing list and get interesting news and updates directly to your inbox.
Thank you for subscribing.